Valneva (NASDAQ:VALN) Stock Jumps 3.9% – Time to Buy?

Valneva SE Sponsored ADR (NASDAQ:VALN) rose 3.9% on Wednesday. The stock traded as high as $5.73 and last traded at $5.7780. 2,831 shares traded hands during trading, a decline of 95% from the average daily volume of 61,432 shares. The stock had previously closed at $5.56.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valneva in a research note on Monday, September 14th. TD Cowen assumed coverage on shares of Valneva in a report on Tuesday, August 11th. They issued a “buy” rating and a $12.00 target price for the company. One equities research analyst has rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Reduce” and a consensus price target of $9.30.

Valneva Price Performance

The company has a quick ratio of 1.69, a current ratio of 2.16 and a debt-to-equity ratio of 2.04. The stock has a 50 day moving average price of $6.32 and a two-hundred day moving average price of $5.83. The firm has a market cap of $540.40 million, a PE ratio of -2.70 and a beta of 1.53.

Valneva (NASDAQ:VALN) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.21). Valneva had a negative return on equity of 153.20% and a negative net margin of 110.33%. The company had revenue of $39.37 million for the quarter, compared to analyst estimates of $44.17 million. As a group, equities analysts expect that Valneva SE Sponsored ADR will post -1.27 earnings per share for the current year.

About Valneva

Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France. The company develops, manufactures and commercializes vaccines intended to address infectious diseases with significant unmet medical needs, including travel-related illnesses, endemic diseases and emerging public-health threats.

Valneva’s marketed products include IXIARO, a vaccine for Japanese encephalitis, and DUKORAL, an oral vaccine used for protection against cholera and certain types of traveler’s diarrhea.